Key facts
- Dr. Martens has maintained its fiscal 2027 outlook.
- The company cited encouraging wholesale demand in the United States.
- Trading has been in line with expectations since the start of the financial year in April.
- Japan and South Korea are performing well, and European markets are meeting expectations.
- The company's 'Levers for Growth' strategy aims to return the business to growth.
British footwear company Dr. Martens has reaffirmed its financial outlook for fiscal year 2027, driven by strong wholesale demand in the United States, its largest market. The company stated that trading has been in line with expectations since the beginning of its financial year in April.
Dr. Martens also reported positive performance in Japan and South Korea, with European markets meeting expectations despite a challenging consumer environment. The company's strategic objectives include driving full-price revenue in the UK and DACH regions, launching an innovative sandal range, opening new retail concepts globally, and unlocking operating model and technology benefits.
In fiscal year 2025, Dr. Martens experienced a 10% decrease in net revenue, totaling 787.6 million pounds, which was in line with guidance. The company's net debt reduced to 249.5 million pounds from 359.8 million pounds in the previous fiscal year. Net profit for fiscal 2025 was 4.5 million pounds, a significant decrease from 69.2 million pounds in fiscal 2024.
Chief Executive Officer Ije Nwokorie highlighted the company's 'Levers for Growth' strategy, aimed at shifting the business to a consumer-first mindset and driving profitable revenue growth through product expansion, improved omnichannel experiences, increased consumer engagement, and a simplified organizational model. The company's autumn/winter order books globally are reported as healthy.